Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06693687 · ClinicalTrials.gov registry record · NA
A Study of the ApricityCare Program for Early Detection and Management of Treatment-Related Adverse Events in Patients With Cancer
A NA study of Metastatic Cancer, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 425
- Enrollment target
- 1
- Study location
NCT06693687 is a NA study of Metastatic Cancer that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 425 participants, roughly in line with the 440-participant average among 109 other Metastatic Cancer trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT06693687, a NA study of Metastatic Cancer, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 425 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate the rate of therapy discontinuation due to toxicity (side effects) among participants with cancer using ApricityCare. Investigators want to learn if identification of early clinical signs of irAEs with timely treatment can prevent severity progression and reduce treatment discontinuation.
Conditions Studied
Interventions
- BEHAVIORAL Metastatic Cancer
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 425 participants |
| Start Date | 2024-12-18 |
| Est. Completion | 2027-11-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06693687
The ClinicalTrials.gov registry entry for NCT06693687 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 425 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 440-participant average among 109 other Metastatic Cancer trials with a reported enrollment target. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which Metastatic Cancer is the first listed.
NCT06693687 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06693687 about?
NCT06693687 is a clinical study titled "A Study of the ApricityCare Program for Early Detection and Management of Treatment-Related Adverse Events in Patients With Cancer". To evaluate the rate of therapy discontinuation due to toxicity (side effects) among participants with cancer using ApricityCare. Investigators want to learn if identification of early clinical signs of irAEs with timely treatment can prevent severity progression and reduce treatment discontinuatio...
What is the current status of trial NCT06693687?
This trial is currently recruiting. It is a NA study. The enrollment target is 425 participants. The study started on 2024-12-18. Estimated completion is 2027-11-01.
What conditions does trial NCT06693687 study?
This clinical trial studies the following conditions: Metastatic Cancer.
What interventions are being tested in trial NCT06693687?
The interventions under investigation include: Metastatic Cancer (BEHAVIORAL).
Who is sponsoring clinical trial NCT06693687?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06693687 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Longitudinal Screening for Financial Hardship to Improve Outcomes in Patients With Advanced Cancer
RECRUITING · NA
-
PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
RECRUITING · NA
-
Comparison of Whole Body DWI to FDG PET
RECRUITING · NA
-
Palliative Spatially Fractionated (GRID) Radiotherapy Using Intensity Modulated Proton Therapy
RECRUITING · NA
-
COBRA: Cancer, Older Adults, Balance and Resistance Activities
RECRUITING · NA
-
Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.